Drugs facing NCE-1 in 2023
Drugs becoming eligible for first Paragraph IV ANDA filing in 2023
1. Accrufer patent expiration
ACCRUFER's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9802973 | SHIELD TX | Crystalline forms of ferric maltol |
Oct, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9248148 | SHIELD TX | Mono (iron hydroxypyrone) and combination (iron hydroxypyrone and GI inflammation inhibiting agents) compositions for anaemia or H. pylori infections |
Mar, 2031
(4 years from now) | |
| US10179120 | SHIELD TX | Dosage regimen of ferric trimaltol |
Jan, 2035
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 25, 2024 |
| New Patient Population(NPP) | Dec 19, 2028 |
Drugs and Companies using FERRIC MALTOL ingredient
NCE-1 date: 26 July, 2023
Market Authorisation Date: 25 July, 2019
Treatment: Method of treating iron deficiency
Dosage: CAPSULE
More Information on Dosage
ACCRUFER family patents
2. Aklief patent expiration
AKLIEF's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7807708 | GALDERMA | Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof |
Jul, 2031
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8470871 | GALDERMA | Ligands that modulate RAR receptors |
Dec, 2025
(3 months ago) | |
| US8227507 | GALDERMA | Ligands that modulate RAR receptors |
Dec, 2025
(3 months ago) | |
| US9084778 | GALDERMA | Topical compositions containing a retinoid of the oil-in-water emulsion type |
May, 2033
(7 years from now) | |
| US9498465 | GALDERMA | Topical compositions in the form of a gel containing a particular solubilized retinoid |
May, 2033
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 04, 2024 |
Drugs and Companies using TRIFAROTENE ingredient
NCE-1 date: 05 October, 2023
Market Authorisation Date: 04 October, 2019
Treatment: Method of activating rargamma receptor; Topical treatment of acne vulgaris; Treatment of acne vulgaris
Dosage: CREAM
How can I launch a generic of AKLIEF before its drug patent expiration?
More Information on Dosage
AKLIEF family patents
3. Aubagio patent
expiration
AUBAGIO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5459163 | SANOFI | Medicament to combat autoimmune diseases |
Oct, 2012
(13 years ago) | |
| US5679709 | SANOFI | Medicaments to combat autoimmune diseases |
Oct, 2014
(11 years ago) | |
| US6794410 | SANOFI | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Sep, 2026
(5 months from now) | |
|
US6794410 (Pediatric) | SANOFI | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis |
Mar, 2027
(11 months from now) | |
| US8802735 | SANOFI | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
Sep, 2030
(4 years from now) | |
|
US8802735 (Pediatric) | SANOFI | (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability |
Mar, 2031
(4 years from now) | |
| US9186346 | SANOFI | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Feb, 2034
(7 years from now) | |
|
US9186346 (Pediatric) | SANOFI | Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients |
Aug, 2034
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 12, 2017 |
| M(M-61) | Apr 30, 2024 |
| Pediatric Exclusivity(PED) | Oct 30, 2024 |
Drugs and Companies using TERIFLUNOMIDE ingredient
NCE-1 date: 31 October, 2023
Market Authorisation Date: 12 September, 2012
Treatment: Treatment of patients with relapsing forms of multiple sclerosis; Treatment of patients with relapsing forms of multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction...
Dosage: TABLET
How can I launch a generic of AUBAGIO before its drug patent expiration?
More Information on Dosage
AUBAGIO family patents
4. Austedo patent expiration
AUSTEDO IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8524733 | TEVA | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Apr, 2031
(5 years from now) | |
| US9550780 | TEVA | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8524733 (Pediatric) | TEVA | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Oct, 2031
(5 years from now) | |
| US9233959 | TEVA | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(7 years from now) | |
| US9814708 | TEVA | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(7 years from now) | |
| US11666566 | TEVA | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(7 years from now) | |
| US9296739 | TEVA | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(7 years from now) | |
|
US9296739 (Pediatric) | TEVA | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(7 years from now) | |
|
US9233959 (Pediatric) | TEVA | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(7 years from now) | |
|
US9550780 (Pediatric) | TEVA | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(7 years from now) | |
|
US9814708 (Pediatric) | TEVA | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(7 years from now) | |
|
US11666566 (Pediatric) | TEVA | Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Mar, 2034
(7 years from now) | |
| US12016858 | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(9 years from now) | |
| US11648244 | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(9 years from now) | |
| US11446291 | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(9 years from now) | |
| US11564917 | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(9 years from now) | |
| US10959996 | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(9 years from now) | |
| US11357772 | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(9 years from now) | |
|
US11648244 (Pediatric) | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(10 years from now) | |
|
US11564917 (Pediatric) | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(10 years from now) | |
|
US10959996 (Pediatric) | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(10 years from now) | |
|
US12016858 (Pediatric) | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(10 years from now) | |
|
US11357772 (Pediatric) | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(10 years from now) | |
|
US11446291 (Pediatric) | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Sep, 2036
(10 years from now) | |
| US11179386 | TEVA | Analogs of deutetrabenazine, their preparation and use |
Mar, 2038
(11 years from now) | |
| US11813232 | TEVA | Analogs of deutetrabenazine, their preparation and use |
Mar, 2038
(11 years from now) | |
|
US11179386 (Pediatric) | TEVA | Analogs of deutetrabenazine, their preparation and use |
Sep, 2038
(12 years from now) | |
|
US11813232 (Pediatric) | TEVA | Analogs of deutetrabenazine, their preparation and use |
Sep, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-751) | Aug 30, 2020 |
| New Chemical Entity Exclusivity(NCE) | Apr 03, 2022 |
| Orphan Drug Exclusivity(ODE) | Apr 03, 2024 |
| Orphan Drug Exclusivity(ODE-134) | Apr 03, 2024 |
| M(M-54) | Jun 24, 2024 |
| Pediatric Exclusivity(PED) | Dec 24, 2024 |
Drugs and Companies using DEUTETRABENAZINE ingredient
NCE-1 date: 25 December, 2023
Market Authorisation Date: 03 April, 2017
Treatment: A method of treating huntington's chorea; Treatment of tardive dyskinesia
Dosage: TABLET
How can I launch a generic of AUSTEDO before its drug patent expiration?
More Information on Dosage
AUSTEDO family patents
5. Balversa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8895601 | JANSSEN | Pyrazolyl quinoxaline kinase inhibitors |
Apr, 2033
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9464071 | JANSSEN | Pyrazolyl quinoxaline kinase inhibitors |
Apr, 2031
(5 years from now) | |
| US9902714 | JANSSEN | Quinoxaline derivatives useful as FGFR kinase modulators |
Mar, 2035
(8 years from now) | |
| US12037644 | JANSSEN | Use of FGFR mutant gene panels in identifying cancer patients that will be responsive to treatment with an FGFR inhibitor |
Oct, 2035
(9 years from now) | |
| US10898482 | JANSSEN | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N'-1 methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
Feb, 2036
(9 years from now) | |
| US11684620 | JANSSEN | Pharmaceutical compositions comprising N-(3,5-dimethoxyphenyl)-N′-(1-methylethyl)-N-[3-(1-methyl-1H-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine |
Feb, 2036
(9 years from now) | |
| US10478494 | JANSSEN | FGFR/PD-1 combination therapy for the treatment of cancer |
Aug, 2036
(10 years from now) | |
| US11077106 | JANSSEN | Cancer treatment |
Feb, 2038
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 12, 2024 |
| New Indication(I-930) | Jan 19, 2027 |
Drugs and Companies using ERDAFITINIB ingredient
NCE-1 date: 13 April, 2023
Market Authorisation Date: 12 April, 2019
Treatment: Treatment of adults with locally advanced or metastatic urothelial carcinoma with susceptible fgfr3 genetic alterations whose disease has progressed on or after at least one line of prior systemic the...
Dosage: TABLET
How can I launch a generic of BALVERSA before its drug patent expiration?
More Information on Dosage
BALVERSA family patents
6. Brukinsa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9447106 | BEONE MEDICINES | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators |
Apr, 2034
(8 years from now) | |
| US10927117 | BEONE MEDICINES | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(11 years from now) | |
| US11851437 | BEONE MEDICINES | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10570139 | BEONE MEDICINES | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
Apr, 2034
(8 years from now) | |
| US11142528 | BEONE MEDICINES | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators |
Apr, 2034
(8 years from now) | |
| US11884674 | BEONE MEDICINES | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(11 years from now) | |
| US11591340 | BEONE MEDICINES | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(11 years from now) | |
| US11970500 | BEONE MEDICINES | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)- 2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
Aug, 2037
(11 years from now) | |
| US11701357 | BEONE MEDICINES | Treatment of B cell cancers using a combination comprising Btk inhibitors |
Jun, 2039
(13 years from now) | |
| US12233069 | BEONE MEDICINES | Oral solid tablet comprising Bruton's Tyrosine Kinase inhibitor and preparation method therefor |
Jun, 2040
(14 years from now) | |
| US11786531 | BEONE MEDICINES | Methods of treating B-cell proliferative disorder |
Jan, 2043
(16 years from now) | |
| US11896596 | BEONE MEDICINES | Methods of treating B-cell proliferative disorder |
Jan, 2043
(16 years from now) | |
| US11911386 | BEONE MEDICINES | Methods of treating B-cell proliferative disorder |
Jan, 2043
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-871) | Aug 31, 2024 |
| New Indication(I-874) | Sep 14, 2024 |
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2024 |
| New Indication(I-817) | Jan 19, 2026 |
| Orphan Drug Exclusivity(ODE-276) | Nov 14, 2026 |
| New Indication(I-936) | Mar 07, 2027 |
| Orphan Drug Exclusivity(ODE-371) | Aug 31, 2028 |
| Orphan Drug Exclusivity(ODE-370) | Sep 14, 2028 |
| ODE*(ODE*) | Jan 19, 2030 |
| Orphan Drug Exclusivity(ODE-274) | Jan 19, 2030 |
| Orphan Drug Exclusivity(ODE-467) | Mar 07, 2031 |
Drugs and Companies using ZANUBRUTINIB ingredient
NCE-1 date: 15 November, 2023
Market Authorisation Date: 14 November, 2019
Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with small lymphocytic lymphoma; Treatment of adult patients with chroni...
Dosage: CAPSULE; TABLET
How can I launch a generic of BRUKINSA before its drug patent expiration?
More Information on Dosage
BRUKINSA family patents
7. Caplyta patent expiration
CAPLYTA's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE39680 | INTRA CELLULAR | Substituted heterocycle fused gamma-carbolines |
Jun, 2020
(5 years ago) | |
| US7183282 | INTRA CELLULAR | Substituted heterocycle fused γ-carbolines |
Jun, 2020
(5 years ago) | |
| US9586960 | INTRA CELLULAR | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de] quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms |
Mar, 2029
(2 years from now) | |
| USRE48825 | INTRA CELLULAR | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid salt crystal forms |
Mar, 2029
(2 years from now) | |
| US8648077 | INTRA CELLULAR | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals |
Dec, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10464938 | INTRA CELLULAR | Pharmaceutical compositions comprising ((6bR,10aS)-1-(4-fluorophenyl)-4-(3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)butan-1-one or pharmaceutically acceptable salts thereof |
Mar, 2028
(1 year, 11 months from now) | |
| US9199995 | INTRA CELLULAR | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-fluorophenyl)-1-butanone toluenesulfonic acid addition salt and salt crystals |
Mar, 2029
(2 years from now) | |
| US9616061 | INTRA CELLULAR | Methods and compositions for sleep disorders and other disorders |
May, 2029
(3 years from now) | |
| US10117867 | INTRA CELLULAR | Methods and compositions for sleep disorders and other disorders |
May, 2029
(3 years from now) | |
| US9168258 | INTRA CELLULAR | Methods and compositions for sleep disorders and other disorders |
May, 2029
(3 years from now) | |
| US8598119 | INTRA CELLULAR | Methods and compositions for sleep disorders and other disorders |
Dec, 2029
(3 years from now) | |
| USRE48839 | INTRA CELLULAR | Methods and compositions for sleep disorders and other disorders |
Aug, 2033
(7 years from now) | |
| US11026951 | INTRA CELLULAR | Methods of treating bipolar disorder |
Dec, 2034
(8 years from now) | |
| US9956227 | INTRA CELLULAR | Method for the treatment of residual symptoms of schizophrenia |
Dec, 2034
(8 years from now) | |
| US10960009 | INTRA CELLULAR | Methods of treating schizophrenia and depression |
Dec, 2034
(8 years from now) | |
| US12409176 | INTRA CELLULAR | Methods Of Treating Acute Depression |
Mar, 2039
(12 years from now) | |
| US11052084 | INTRA CELLULAR | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
Aug, 2039
(13 years from now) | |
| US11690842 | INTRA CELLULAR | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
Aug, 2039
(13 years from now) | |
| US10695345 | INTRA CELLULAR | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
Aug, 2039
(13 years from now) | |
| US12128043 | INTRA CELLULAR | Pharmaceutical capsules comprising lumateperone mono-tosylate |
Aug, 2039
(13 years from now) | |
| US12070459 | INTRA CELLULAR | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
Aug, 2039
(13 years from now) | |
| US11806348 | INTRA CELLULAR | Methods of treatment using pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
Aug, 2039
(13 years from now) | |
| US11980617 | INTRA CELLULAR | Methods of treating acute depression and/or acute anxiety |
Oct, 2039
(13 years from now) | |
| US12090155 | INTRA CELLULAR | Methods |
Jul, 2040
(14 years from now) | |
| US12410195 | INTRA CELLULAR | Pharmaceutical Compositions Comprising 4-((6Br,10As)-3-Methyl-2,3,6B,9,10,10A-Hexahydro-1H-Pyrido[3′,4′:4,5]Pyrrolo[1,2,3-De]Quinoxalin-8(7H)-Yl)-1-(4-((6Br,10As)-3-Methyl-2,3,6B,9,10,10A-Hexahydro-1H-Pyrido[3′,4′:4,5]Pyrrolo[1,2,3-De]Quinoxalin-8(7H)-Yl)Phenyl)Butan-1-One For Treating Conditions Of The Central Nervous System And Cardiac Disorders |
Dec, 2040
(14 years from now) | |
| US11753419 | INTRA CELLULAR | 4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders |
Dec, 2040
(14 years from now) | |
| US12122792 | INTRA CELLULAR | Pharmaceutical compositions comprising 4-((6bR,10aS)-3-methyl2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin8(7H)-yl)-1-(4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H-pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl)phenyl)butan-1-one for treating conditions of the central nervous system and cardiac disorders |
Dec, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-882) | Dec 17, 2024 |
| New Chemical Entity Exclusivity(NCE) | Dec 20, 2024 |
| New Indication(I-904) | Nov 05, 2028 |
Drugs and Companies using LUMATEPERONE TOSYLATE ingredient
NCE-1 date: 21 December, 2023
Market Authorisation Date: 22 April, 2022
Treatment: Modulation of 5-hydroxytryptamine 2 receptor activity in schizophrenia; Treatment of bipolar depression; Treatment of schizophrenia; Treatment of bipolar disorder i, bipolar disorder ii, or bipolar de...
Dosage: CAPSULE
How can I launch a generic of CAPLYTA before its drug patent expiration?
More Information on Dosage
CAPLYTA family patents
8. Dalvance patent expiration
DALVANCE's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7115564 | ABBVIE | Stable pharmaceutical compositions of dalbavancin and methods of administration |
Nov, 2023
(2 years ago) | |
| US7119061 | ABBVIE | Dalbavancin compositions for treatment of bacterial infections |
Nov, 2023
(2 years ago) | |
| US8143212 | ABBVIE | Dalbavancin compositions for treatment of bacterial infections |
Nov, 2023
(2 years ago) | |
| US6900175 | ABBVIE | Methods of administering dalbavancin for treatment of bacterial infections |
May, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-154) | Jan 20, 2019 |
| New Chemical Entity Exclusivity(NCE) | May 23, 2019 |
| Generating Antibiotic Incentives Now(GAIN) | May 23, 2024 |
| New Patient Population(NPP) | Jul 22, 2024 |
Drugs and Companies using DALBAVANCIN HYDROCHLORIDE ingredient
NCE-1 date: 24 May, 2023
Market Authorisation Date: 23 May, 2014
Treatment: Treatment of bacterial infections using a two-dose regimen of dalbavancin.; Treatment of acute bacterial skin and skin structure infections (absssi) in adult and pediatric patients using a two-dose re...
Dosage: POWDER
How can I launch a generic of DALVANCE before its drug patent expiration?
More Information on Dosage
DALVANCE family patents
9. Exem Foam Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9034300 | GISKIT | Composition and method for medical imaging of body cavities |
Oct, 2030
(4 years from now) | |
| US9259494 | GISKIT | Composition and method for medical imaging of body cavities |
May, 2035
(9 years from now) | |
| US9849199 | GISKIT | Composition and method for medical imaging of body cavities |
Feb, 2036
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 07, 2024 |
Drugs and Companies using AIR POLYMER-TYPE A ingredient
NCE-1 date: 08 November, 2023
Market Authorisation Date: 07 November, 2019
Treatment: Use in sonohysterosalpinography to assess fallopian tube patency
Dosage: FOAM
More Information on Dosage
EXEM FOAM KIT family patents
10. Fetroja patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9238657 | SHIONOGI | Cephalosporin having catechol group |
Nov, 2033
(7 years from now) | |
| US10004750 | SHIONOGI | Salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof |
Sep, 2035
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9949982 | SHIONOGI | Preparation containing cephalosporin having a catechol moiety |
Sep, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-844) | Sep 25, 2023 |
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2024 |
| Generating Antibiotic Incentives Now(GAIN) | Nov 14, 2029 |
Drugs and Companies using CEFIDEROCOL SULFATE TOSYLATE ingredient
NCE-1 date: 15 November, 2023
Market Authorisation Date: 14 November, 2019
Treatment: Method of treating hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (habp/vabp) comprising administering cefiderocol sulfate tosylate
Dosage: POWDER
More Information on Dosage
FETROJA family patents